FDA Will Move Faster To Ban Bad Actors From Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Recent changes will speed FDA's process for barring non-compliant clinical trial investigators from future product research, agency staffers say
You may also be interested in...
Clinical Researcher Debarments Proceeding Slowly, Despite FDA Promises Of Reform
It still takes years to debar a physician convicted of a crime from conducting clinical research.
FDA Will Revise Investigator Disqualification Regs In Response To GAO Report
The agency will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories.
FDA Will Revise Investigator Disqualification Regs In Response To GAO Report
FDA will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories